Abstract:In this work, a pH‐driven membrane‐anchored near‐infrared dual type (type I and II) nano‐photosensitizer, YBS‐BMS NPs‐RKC, is developed for prostate cancer dual‐pronged immunotherapy. In vitro and in vivo studies have shown that this dual‐pronged therapy stimulates a powerful antitumor immune response to suppress primary tumor progression and evokes long‐term immune memory to inhibit tumor relapse and metastasis. Prostate cancer (PCa) is a frustrating immunogenic "cold" tumor and generally receives unsatisfied immunotherapy outcomes in the clinic. Pyroptosis is an excellent immunogenic cell death form that can effectively activate the antitumor immune response, promote cytotoxic T‐lymphocyte infiltration, and convert tumors from "cold" to "hot." However, the in vivo application of pyroptosis drugs is seriously limited, and the upregulation of tumor PD‐L1 caused by photo‐immunotherapy further promotes immune escape. Herein, a new nano‐photosensitizer (YBS‐BMS NPs‐RKC) with pH‐response integrating immunogenic pyroptosis induction and immune checkpoint blockade is developed. The pH‐responsive polymer equipped with the cell membrane anchoring peptide RKC is used as the carrier and further encapsulated with the near‐infrared‐activated semiconductor polymer photosensitizer YBS and a PD‐1/PD‐L1 complex small molecule inhibitor BMS‐202. The pH‐driven membrane‐anchoring and pyroptosis activation of YBS‐BMS NPs‐RKC is clearly demonstrated. In vitro and in vivo studies have shown that this dual‐pronged therapy stimulates a powerful antitumor immune response to suppress primary tumor progression and evokes long‐term immune memory to inhibit tumor relapse and metastasis. This work provides an effective self‐synergistic platform for PCa immunotherapy and a new idea for developing more biocompatible photo‐controlled pyroptosis inducers.

Photo‐Activatable Silencing Extracellular Vesicle (PASEV) Sensitizes Cancer Immunotherapy

Photoactivatable Silencing Extracellular Vesicle (PASEV) Sensitizes Cancer Immunotherapy

Antitumor synergism between PAK4 silencing and immunogenic phototherapy of engineered extracellular vesicles

Engineered Extracellular Vesicles Expressing Siglec‐10 Camouflaged AIE Photosensitizer to Reprogram Macrophages to Active M1 Phenotype and Present Tumor‐Associated Antigens for Photodynamic Immunotherapy

ROS-Responsive Self-activatable Photosensitizing Agent for Photodynamic-Immunotherapy of cancer

Förster Resonance Energy Transfer Nanobullet for Photoacoustic Imaging and Amplified Photothermal‐Photodynamic Therapy of Cancer

Photoactivatable nanoagonists chemically programmed for pharmacokinetic tuning and in situ cancer vaccination

A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy

Drug-drug conjugates self-assembled nanomedicines triggered photo-/immuno- therapy for synergistic cancer treatments

Biomimetic Nano‐Photosensitizer Amplifies Immunogenic Pyroptosis and Triggers Synergistic Cancer Therapy

Photoimmunotherapy-Induced Pyroptosis Remodels the Microenvironment to Enhance Cancer Immunotherapy

Rationally Integrated Precise ER‐targeted And Oxygen‐compensated Photodynamic Immunostimulant for Immunogenicity‐boosted Tumor Therapy

Tumor Microenvironment Activated Chemodynamic–Photodynamic Therapy by Multistage Self‐Assembly Engineered Protein Nanomedicine

Full‐active Pharmaceutical Ingredient Nanosensitizer for Augmented Photoimmunotherapy by Synergistic Mitochondria Targeting and Immunogenic Death Inducing

Acidity-activatable dynamic hybrid nanoplatforms derived from extracellular vesicles of M1 macrophages enhance cancer immunotherapy through synergistic triple immunotherapy

Branched Polymer‐Based Redox/Enzyme‐Activatable Photodynamic Nanoagent to Trigger STING‐Dependent Immune Responses for Enhanced Therapeutic Effect

Dual‐Pronged Attack: pH‐Driven Membrane‐Anchored NIR Dual‐Type Nano‐Photosensitizer Excites Immunogenic Pyroptosis and Sequester Immune Checkpoint for Enhanced Prostate Cancer Photo‐Immunotherapy

In Vivo-assembled phthalocyanine/albumin supramolecular complexes combined with a hypoxia-activated prodrug for enhanced photodynamic immunotherapy of cancer

Biointerface‐Engineered Hybrid Nanovesicles for Targeted Reprogramming of Tumor Microenvironment

Expanded ROS Generation and Hypoxia Reversal: Excipient‐free Self‐assembled Nanotheranostics for Enhanced Cancer Photodynamic Immunotherapy

An enzyme-responsive and transformable PD-L1 blocking peptide-photosensitizer conjugate enables efficient photothermal immunotherapy for breast cancer